Arbutus Biopharma Corp Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Arbutus Biopharma Corp (ABUS) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $41.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-23
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $41.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $133.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $271.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $450.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $41.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $133.00K 10-K · filed 2025-03-27 |
| 2023-12-31 | $271.00K 10-K · filed 2024-03-05 |
| 2022-12-31 | $450.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $664.00K 10-K · filed 2022-03-03 |
| 2020-12-31 | $911.00K 10-K · filed 2021-03-04 |
| 2019-12-31 | $1.19M 10-K · filed 2020-03-05 |
| 2019-09-30 | $1.27M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.34M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $1.43M 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |